P3, N=992, Completed, AbbVie | Active, not recruiting --> Completed

L-THP reduced the FSP1 stability to trigger the ferroptosis of GC cells. In conclusion, this study shows that L-THP synergizes cytotoxic CD8+ T cell-mediated GC antitumor response and ferroptosis through FSP1, providing potent evidence for GC immunoregulation.

P2, N=112, Completed, Yale University | Phase classification: P1/2 --> P2

Moreover, these ligands significantly suppressed the hTERT mRNA expression (1.00 for control, 0.43 ± 0.02 for l-THP, 0.19 ± 0.01 for M1, 0.33 ± 0.03 for M2) and showed the potent antitumor activity in A549 cells and lung cancer xenograft model. Collectively, these findings establish l-THP and its derivatives as the promising lead compounds for the development of chemotherapeutics against non-small cell lung cancer as well as provide the plausible mechanism insights into potent antitumor activity.

P=N/A, N=0, Available, AbbVie

P1, N=83, Completed, AbbVie | Active, not recruiting --> Completed

P1, N=83, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting

P1, N=84, Recruiting, AbbVie | Not yet recruiting --> Recruiting

P1, N=84, Not yet recruiting, AbbVie

Further analysis pinpointed key compound-target pairs, including Berberine targeting CYP1A1, and Honokiol, Tangeretin, α-Cyperone, 1-O-Acetylbritannilactone, Rotundine B, Cyperolone targeting HMOX1...Our findings offered a comprehensive insight into GERD treatment and herbal intervention, enhancing our understanding of accurate network pharmacology. It suggested that concentrating on a single pathway, specifically the ROS signaling pathway, could serve as a new therapeutic strategy for herbal medicine in GERD treatment.

P2, N=41, Completed, Cerevel Therapeutics, LLC | Active, not recruiting --> Completed | N=75 --> 41

P1/2, N=112, Completed, Yale University | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Mar 2024